Spotlight
Commentary
Cultural Corner
Psychiatric Practice
Series
News
Job Board
CME/CE
Partners
Editorial
Subscribe
What’s New?
Acne patients are benefitting from a robust pipeline with treatments that hold promise for increased efficacy and safety. First-in-class additions to the FDA-approved armamentarium, such as the novel antiandrogen clascoterone (Winlevi; Sun Pharma), give dermatologists and pediatricians new tools to combat this skin condition. Speakers offer insights on matching medications to individual patient needs and controlling costs.
Related Videos
Related Content
